FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2782245280> ?p ?o ?g. }

• W2782245280 endingPage "24167" @default.
• W2782245280 startingPage "24155" @default.
• W2782245280 abstract "// Yating Li 1 , Hong Xu 2 , Wenrui Wu 1 , Jianzhong Ye 1 , Daiqiong Fang 1 , Ding Shi 1 and Lanjuan Li 1 1 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University, Hangzhou 31003, People’s Republic of China 2 Department of Orthopaedics, Tianjin Medical University General Hospital, Heping District, Tianjin 300052, People’s Republic of China Correspondence to: Lanjuan Li, email: ljli@zju.edu.cn Keywords: NAFLD (non-alcoholic fatty liver disease); ARBs (angiotensin receptor blockers); liver fibrosis; liver inflammation; meta-analysis Received: September 19, 2017      Accepted: October 27, 2017      Epub: January 02, 2018      Published: May 08, 2018 ABSTRACT Objective: Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases, ranging from simple steatosis to progressive steatohepatitis and cirrhosis. Because of their anti-inflammatory and anti-fibrotic effects, angiotensin receptor blockers (ARBs) are potential therapeutic agents for NAFLD. The present systematic review assessed the effectiveness of ARBs in NAFLD management. Results: Accounting for data overlap and exclusion criteria, randomized controlled trial -based and single-arm meta-analyses were conducted for four studies with 362 patients and eight studies with 525 patients, respectively. Although alanine aminotransferase levels were not significantly affected by ARB treatment (standardized mean difference 0.20; 95% confidence interval (CI) [−0.04, 0.44]; P = 0.10), a fixed-effect model revealed a decreasing trend in alanine transaminase levels. Low-density lipoprotein levels were reduced by ARB treatment (MD 5.21; 95% CI [3.01, 7.40]; P < 0.00001), and total cholesterol also decreased in response to ARBs (MD 2.10; 95% CI [−0.37, 4.57]; P = 0.10). However, the fibrosis score and NAFLD activity score were not significantly improved by ARB treatment (MD 0.10; 95% CI [−0.58, 0.78]; P = 0.77) (MD −0.25; 95% CI [−1.05, 0.55]; P = 0.53). Materials and Methods: Keywords were used to identify studies in PubMed, EMBASE, CENTRAL, Web of Science and CNKI published up to July 31, 2017. Single-arm and RCT-based meta-analyses of the available data were performed using RevMan (version 5.3). Conclusions: Although ARBs significantly decreased plasma low-density lipoprotein and total cholesterol levels, the current evidence is insufficient to support the efficacy of ARBs in managing fibrosis in NAFLD patients." @default.
• W2782245280 created "2018-01-12" @default.
• W2782245280 creator A5016293320 @default.
• W2782245280 creator A5035757682 @default.
• W2782245280 creator A5049017147 @default.
• W2782245280 creator A5079175227 @default.
• W2782245280 creator A5082079047 @default.
• W2782245280 creator A5082726019 @default.
• W2782245280 date "2018-01-02" @default.
• W2782245280 modified "2023-09-30" @default.
• W2782245280 title "Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis" @default.
• W2782245280 cites W1606133142 @default.
• W2782245280 cites W1931347061 @default.
• W2782245280 cites W1963549723 @default.
• W2782245280 cites W1968231063 @default.
• W2782245280 cites W1968969864 @default.
• W2782245280 cites W1971467647 @default.
• W2782245280 cites W1984611853 @default.
• W2782245280 cites W1984870942 @default.
• W2782245280 cites W1987491599 @default.
• W2782245280 cites W2001509811 @default.
• W2782245280 cites W2004561550 @default.
• W2782245280 cites W2008731450 @default.
• W2782245280 cites W2010428766 @default.
• W2782245280 cites W2025743530 @default.
• W2782245280 cites W2037327641 @default.
• W2782245280 cites W2044710035 @default.
• W2782245280 cites W2052299150 @default.
• W2782245280 cites W2059307783 @default.
• W2782245280 cites W2062618014 @default.
• W2782245280 cites W2070761972 @default.
• W2782245280 cites W2086475276 @default.
• W2782245280 cites W2090600610 @default.
• W2782245280 cites W2094842922 @default.
• W2782245280 cites W2096064097 @default.
• W2782245280 cites W2117291046 @default.
• W2782245280 cites W211731429 @default.
• W2782245280 cites W2125523029 @default.
• W2782245280 cites W2132047707 @default.
• W2782245280 cites W2139638393 @default.
• W2782245280 cites W2148774637 @default.
• W2782245280 cites W2152425011 @default.
• W2782245280 cites W2157630219 @default.
• W2782245280 cites W2159499517 @default.
• W2782245280 cites W2160887608 @default.
• W2782245280 cites W2161096403 @default.
• W2782245280 cites W2236539608 @default.
• W2782245280 cites W2292998606 @default.
• W2782245280 cites W23581341 @default.
• W2782245280 cites W239124720 @default.
• W2782245280 cites W2522533101 @default.
• W2782245280 cites W2522715783 @default.
• W2782245280 cites W2556419785 @default.
• W2782245280 cites W2576635225 @default.
• W2782245280 cites W2605795744 @default.
• W2782245280 cites W3143409077 @default.
• W2782245280 cites W89846141 @default.
• W2782245280 cites W936190239 @default.
• W2782245280 doi "https://doi.org/10.18632/oncotarget.23816" @default.
• W2782245280 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5963622" @default.
• W2782245280 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29844879" @default.
• W2782245280 hasPublicationYear "2018" @default.
• W2782245280 type Work @default.
• W2782245280 sameAs 2782245280 @default.
• W2782245280 citedByCount "21" @default.
• W2782245280 countsByYear W27822452802019 @default.
• W2782245280 countsByYear W27822452802020 @default.
• W2782245280 countsByYear W27822452802021 @default.
• W2782245280 countsByYear W27822452802022 @default.
• W2782245280 countsByYear W27822452802023 @default.
• W2782245280 crossrefType "journal-article" @default.
• W2782245280 hasAuthorship W2782245280A5016293320 @default.
• W2782245280 hasAuthorship W2782245280A5035757682 @default.
• W2782245280 hasAuthorship W2782245280A5049017147 @default.
• W2782245280 hasAuthorship W2782245280A5079175227 @default.
• W2782245280 hasAuthorship W2782245280A5082079047 @default.
• W2782245280 hasAuthorship W2782245280A5082726019 @default.
• W2782245280 hasBestOaLocation W27822452801 @default.
• W2782245280 hasConcept C126322002 @default.
• W2782245280 hasConcept C2778772119 @default.
• W2782245280 hasConcept C2779134260 @default.
• W2782245280 hasConcept C2779478299 @default.
• W2782245280 hasConcept C71924100 @default.
• W2782245280 hasConcept C90924648 @default.
• W2782245280 hasConcept C95190672 @default.
• W2782245280 hasConceptScore W2782245280C126322002 @default.
• W2782245280 hasConceptScore W2782245280C2778772119 @default.
• W2782245280 hasConceptScore W2782245280C2779134260 @default.
• W2782245280 hasConceptScore W2782245280C2779478299 @default.
• W2782245280 hasConceptScore W2782245280C71924100 @default.
• W2782245280 hasConceptScore W2782245280C90924648 @default.
• W2782245280 hasConceptScore W2782245280C95190672 @default.
• W2782245280 hasIssue "35" @default.
• W2782245280 hasLocation W27822452801 @default.
• W2782245280 hasLocation W27822452802 @default.
• W2782245280 hasLocation W27822452803 @default.
• W2782245280 hasLocation W27822452804 @default.
• W2782245280 hasOpenAccess W2782245280 @default.

• next